BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s approved treatment for achondroplasia.

​Achondroplasia is a genetic condition that causes dwarfism and stunted growth in children. The recent data reported by the company suggests that starting treatment before the age of 2 years maximizes benefits, including height gains, better body proportions, and arm span. The data showed that kids under 6 months, starting VOXZOGO, showed sustained improvements over 4 years.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) noted that data suggest that more than 5,000 kids in 50+ countries have used VOXZOGO. Data from Japan, Europe, and the US suggest strong results. For instance, kids under 2 years in Japan gained 9.91 cm in 12 months, and 15.62 cm in 24 months.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.